SynthesisPloS one2016
Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Comparative Analytical Performance and Clinical Agreement of Chemiluminescence Microparticle Immunoassay and Electrochemiluminescence Immunoassay for CA19-9: A Diagnostic Accuracy Study.Diagnostics (Basel, Switzerland) · 2026Article
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer.Cell death & disease · 2025Review
- An Isolated Hydatid Cyst of the Spleen with High Serum Levels of CA 19-9-A Meaningful Association or Just a Challenge for Diagnosis? A Case Report.Medicina (Kaunas, Lithuania) · 2025Article
- FJX1 as a candidate diagnostic and prognostic serum biomarker for colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- ELEVATED CA 19-9 IN AN ASYMPTOMATIC PATIENT: WHAT DOES IT MEAN?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2022Article
- hnRNPC Promotes Malignancy in Pancreatic Cancer through Stabilization of IQGAP3.BioMed research international · 2022Article
- Improvement of Diagnostic Accuracy for Pancreatic Cancer with Serum Lactate Dehydrogenase.Cancer management and research · 2021Article
- Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.World journal of gastrointestinal surgery · 2020Review
- The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives.Journal of cellular and molecular medicine · 2020Review
- Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines.Visceral medicine · 2018Review
- Managing Incidental Pancreatic Cysts.Current gastroenterology reports · 2018Review
- Liquid biopsy in pancreatic cancer: the beginning of a new era.Oncotarget · 2018Review
- Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis.Gastroenterology research and practice · 2018Review
- Upregulated exosomic miR‑23b‑3p plays regulatory roles in the progression of pancreatic cancer.Oncology reports · 2017Article
- Pregnancy with concomitant pancreatic cancer.Proceedings (Baylor University. Medical Center) · 2017Article
- A prospective study of endoscopic ultrasonography features, cyst fluid carcinoembryonic antigen, and fluid cytology for the differentiation of small pancreatic cystic neoplasms.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUsing serum carbohydrate antigen 19-9 (CA 19-9) in discriminating between benign and malignant pancreatic disease remains controversial. We aim to evaluate the diagnostic value of serum CA 19-9 in predicting malignant pancreatic cystic lesions.
methodsEligible studies were identified through searching MEDLINE and EMBASE prior to March 2016. Studies were assessed for quality using the Quality Assessment for Studies of Diagnostic Accuracy, 2nd version (QUADAS-2). Pooled sensitivity and specificity with 95% confidence interval (CI) were calculated using random-effects models. Summary receiver operator characteristic (SROC) curves and the area under curve (AUC) were performed.
resultsA total of thirteen studies including 1437 patients were enrolled in this meta-analysis. The pooled sensitivity and specificity were 0.47(95% CI: 0.35-0.59), and 0.88(95% CI: 0.86-0.91), respectively, and the AUC was 0.87(95% CI, 0.84-0.90). Meta-regression analysis showed that sample size, region and reference standards were not the main sources of heterogeneity.
conclusionsSerum CA 19-9 has satisfying pooled specificity while poor pooled sensitivity for discriminating benign from malignant PCNs. It deserves to be widely used as complementary to other clinical diagnostic methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.